The Financial Times Annual FT Global Pharmaceutical and Biotechnology Conference brings together the industry’s top executives and visionaries to explore the latest trends , from keeping pace with developments in digital health and AI to countering the emerging competitors in the healthcare space, and reinventing the business model for the age of the patient.
FT Global Pharmaceutical and Biotechnology Conference
With the support of
Global Clinical Research Partner
Heather Bresch is the Chief Executive Officer of Mylan. She also serves on the company’s board of directors. As CEO, she is responsible for a workforce of more than 35,000, a powerful global research and development platform, a manufacturing footprint comprising more than 50 facilities and a portfolio of more than 7,500 generic
and branded pharmaceuticals sold in more than 165 countries and territories. Throughout her 25-year career with Mylan, Ms Bresch, who started with the company as a data-entry clerk, has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, she served as Mylan’s President, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan’s Chief Operating Officer and Chief Integration Officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled the size of the company. Ms Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare.
Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.
Advisory Board (10)
Virginia (Ginny) Acha has worked in industry and academia throughout her career, combining interests in science policy research and innovation performance within and across organisations. She recently joined MSD to lead regulatory policy efforts for innovation that will lead to better treatment for patients in Europe, the Middle East, Africa and Asia. In particular, she is supporting work on real world evidence and integrated evidence generation. Before joining MSD, Dr Acha was the senior spokesman for the industry in the UK for research, medical and innovation policy. She was responsible for ABPI’s work on Brexit for the life sciences sector. Previously, Dr Acha worked for Amgen in global regulatory policy and for Pfizer working on policy development in science and innovation in healthcare.
Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed in June 2018. She held the post of President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Ms Anson held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams. She joined Zeneca Pharmaceuticals (USA) in 1998 as a business development manager. Prior to this she worked for Salick Health Care (now Aptium), a California based cancer disease management company. Her first position upon graduating from university was with KPMG in London as a management consultant
Ms Anson is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.
Ms Anson holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK.
Alexandra has always considered her life goal to contribute to developing and advancing novel therapies, particularly against age-related diseases. With Apollo she will leverage her scientific and strategic expertise to support new ventures in the development of groundbreaking therapies.
Before Apollo Alexandra was a consultant with The Boston Consulting Group in Munich, where she specialized in buy- and sell-side asset valuations for biotechnology companies and biopharma portfolio strategy. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. She is also a trained pharmacist with expertise in pharmacology and toxicology.
Dr. Mason served as Head of Johnson & Johnson’s London Innovation Centre from October 2015 to April 2018, where he was responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr. Mason led a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early-stage partnerships and investments across all three sectors of J&J.
Prior to joining J&J, Dr Mason was CEO of a venture-backed biotechnology startup, XO1 Ltd. until the company was acquired by Janssen Pharmaceuticals (a subsidiary of J&J) in March 2015. Prior to that, he was Head of Strategy and Business Development and member of Executive Leadership Team at specialty pharmaceutical and medical device company BTG Plc (LON: BTG), where he led its transformation into a leading interventional medicine company through multiple acquisitions including Ekos Corporation, Biocompatibles Plc, and MDS Nordion’s Therasphere business. Dr.Mason also served as an Executive-in-Residence for Advent Venture Partners where he served as a turnaround CEO for several portfolio companies. Prior to that he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT) and member of the CAT Executive Leadership Team.
Dr. Mason trained in Medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from University College, London and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management.
Mark Samuels is Chief Business & Strategy Officer at the Medicines Discovery Catapult. In this role, he is responsible for business development, strategy, communications and research consortia. Previously, Mr Samuels founded the national Office for Clinical Research Infrastructure and was a founder member of the NIHR Strategy Board. With £1.1bn annual budget, the NIHR is responsible for NHS research across England. Mr Samuels also worked with Number 10 on David Cameron’s strategy for life sciences. At HIHR he established the organisation’s Translational Research Collaborations and chaired the creation of the UK’s Stem Cell Transplant Clinical Trials Partnership. Before NIHR, Mr Samuels was an executive at Roche Diagnostics. Representing the UK diagnostics industry, he co-chaired with Sir Andrew Dillon creation of the programme for NICE to evaluate diagnostics and medical devices. Educated at QMUL and Saïd Business School, Mr Samuels holds a Policy Fellowship at Cambridge University.
Mike Standing is the Life Sciences and Healthcare industry leader for Deloitte for EMEA. Mr Standing has consulted to leading pharmaceutical and healthcare organisations in Europe, US and China for over 20 years, focusing on commercial strategy, operations and R&D productivity. In addition, he is currently leading major programmes to understand how real world evidence can transform health outcomes and productivity. He also advises governments on building healthcare clusters and is a member of the UK's Global Medical Excellence Cluster (GMEC) Advisory Board. Prior to joining Deloitte, Mr Standing was Co-Head of Life Sciences for the Monitor Group and Global Head of Capgemini's Life Sciences business. He is a graduate of Durham and Cambridge Universities and is based in London.
- Debate the role of super clusters and industrial strategy in creating a ‘big bang’ in life sciences
- Discover how China’s novel approaches to R&D, data and digital health are creating innovate treatment and service models
- Discuss what it takes for pharma to win in population health management and the business of prevention
- Learn how innovative gene-based therapies are transforming the industry paradigm from treatment to cure and the pricing strategies to manage it.
- Envision the future of diagnostics and personalised medicine
- Hear from leading fund managers, corporate venturers, and other investors on where they are placing bets in pharma
- Be part of the discussion on value and evidence and the challenge of managing the increasing volume and complexity of big data
FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.
The FT Global Pharmaceutical and Biotechnology Conference will be attended by:
- Pharmaceutical companies
- Biotechnology companies
- Diagnostic and medical device
- Healthcare providers and insurers
- Government healthcare departments, HTA’s and drug regulators
- IT, big data and analytics providers
- Health economists
- Healthcare investment bankers, private equity
- Patient representatives and NGOs
- Gain access to 350 Senior Executives from the Digital Health Industry, who will be attending the event;
- Brand alignment with the FT and its unrivalled credibility;
- Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
- Benefit from sustained international visibility through our advertising and marketing campaigns
Commercial Manager, Global Industries
Super Early Bird Rate - Ends on 3rd March
Presented By (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT marks 130 years in 2018 with a record paying readership of more than 940,000, three-quarters of which are digital subscriptions. It is part of Nikkei Inc, which provides a broad range of information, news and services for the global business community.
With the support of (1)
About Life Sciences and Health Care at Deloitte
Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
Global Clinical Research Partner (1)
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.
With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,650 employees. For further information please visit www.iconplc.com Follow @iconplc on Twitter.